Company intelligence / Profile preview

Chestnut Medical Technologies

Menlo Park, California, United Statesbloomberg.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Chestnut Medical Technologies developed the Pipeline Embolization Device for treating cerebral aneurysms—a novel flow-diverting stent that diverts blood away from the aneurysm to promote occlusion while maintaining parent vessel patency. The device received CE Mark approval in Europe and was undergoing pivotal clinical trials for FDA approval at the time of acquisition. Clinical studies compared its safety/effectiveness to coil embolization for wide-necked intracranial aneurysms.

Therapeutic areas: Neurology
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

2 assets

Pipeline Embolization Device

Commercial

Indications: Cerebral aneurysm

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Chestnut Medical Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chestnut Medical Technologies.

Explore the full profile